A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
Viridian Therapeutics, Inc. VRDN
Mixed (early) broader-coverage candidate · Viridian Therapeutics, Inc.
On FrontierLab's discovery record since 2026-07-13 (12 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Mixed (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-09-30), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | 23220.3% |
|---|---|
| Gross margin | 99.6% |
| Gross profits / assets | 0.06 |
| Rule of 40 | 22650.6 |
| Net margin | -569.7% |
| Cash runway (months) | 35.3 |
| PEG | — |
| Price / sales | 31.8 |
Quality checklist
- ~ Revenue growth — 23220.3% (pass ≥ 20%)
- ✗ Capital efficiency
- ✓ Gross margin — 99.6% (pass ≥ 60%)
- ~ Gross-margin trend — -0.4 (pass ≥ 2)
- ✓ Share dilution — 32.2%
Fundamentals — snapshot as of 2026-09-30
| Stage | Early |
|---|---|
| Share issuance (YoY) | 32.2% · heavy issuance |
| Moat | — |
| TAM | — |
| P/E (trailing) | — |
| EPS (trailing) | $-3.53 |
| Burn multiple | 4.7 |
| Gross-margin trend (pts) | -0.4 |
| Cash / assets | 0.89 |
| Net debt / EBITDA | — |
| Statements as of | Q2 FY2026 · filed 2026-08-06 |
Momentum context — a snapshot from 2026-09-30, not current
| Price at surface | $20.00 (as of 2026-09-30) |
|---|---|
| 52-week range | $11.76 – $34.29 |
| % off 52-wk high | -41.7% |
| RSI (14) | 35 |
| Relative volume | 0.7× |
Risk flags
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-09-30 (end-of-day). How grades are computed →